Protocol Ledger

NCT05673993 · Phase III · COMPLETED

A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

Interventional Phase III clinical trial protocol NCT05673993 sponsored by RemeGen Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-06 Enrollment: 381 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05673993
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)381 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05673993
Protocol FieldVerified Registry Value
NCT IdentifierNCT05673993
Consolidated Lead SponsorRemeGen Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment381 participants (ACTUAL)
Registered Start Date2023-04-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI